Coagulation and wound repair during COVID-19

Vineet D Menachery; Lisa E Gralinski

doi:10.1016/j.healun.2021.06.006

Coagulation and wound repair during COVID-19

J Heart Lung Transplant. 2021 Oct;40(10):1076-1081. doi: 10.1016/j.healun.2021.06.006. Epub 2021 Jun 12.

Authors

Vineet D Menachery¹, Lisa E Gralinski²

Affiliations

¹ Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas; World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston Texas; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas. Electronic address: Vimenach@utmb.edu.
² Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina. Electronic address: lgralins@email.unc.edu.

Abstract

While COVID-19 is best known as a respiratory infection, SARS-CoV-2 causes systemic disease manifestations including coagulopathies. Both dysregulated extracellular matrix remodeling pathways and circulating coagulation proteins are hallmarks of severe COVID-19 and often continue after the resolution of acute infection. Coagulation proteins have proven effective as biomarkers for severe disease and anticoagulants are a mainstay of COVID-19 therapeutics in hospitalized patients. While much knowledge has been gained about the role of clotting pathway activation in COVID-19, much remains to be elucidated in this complex network of signaling pathways.

Keywords: COVID-19; SARS-CoV-2; coagulation; coronavirus; fibrinolysis.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Blood Coagulation Disorders / etiology*
COVID-19 / complications*
COVID-19 / physiopathology*
Humans
Wound Healing*

Abstract

Publication types

MeSH terms

Grants and funding